Rhenman & Partners Asset Management AB Decreases Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Rhenman & Partners Asset Management AB trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 66.2% during the fourth quarter, Holdings Channel reports. The institutional investor owned 17,000 shares of the biopharmaceutical company’s stock after selling 33,350 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in Alnylam Pharmaceuticals were worth $4,000,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Larson Financial Group LLC raised its holdings in shares of Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 73 shares in the last quarter. R Squared Ltd acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at $33,000. OFI Invest Asset Management acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at $35,000. Versant Capital Management Inc lifted its holdings in Alnylam Pharmaceuticals by 77.6% during the 4th quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 83 shares during the last quarter. Finally, Quantbot Technologies LP boosted its position in shares of Alnylam Pharmaceuticals by 1,754.5% during the 3rd quarter. Quantbot Technologies LP now owns 204 shares of the biopharmaceutical company’s stock worth $56,000 after acquiring an additional 193 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the transaction, the executive vice president now directly owns 12,881 shares of the company’s stock, valued at $3,240,344.36. The trade was a 10.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Jeffrey V. Poulton sold 967 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total transaction of $246,749.39. Following the completion of the sale, the chief financial officer now directly owns 32,786 shares of the company’s stock, valued at $8,366,003.62. The trade was a 2.86 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 71,234 shares of company stock valued at $19,958,097. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $235.74 on Friday. The stock has a fifty day moving average price of $259.03 and a 200 day moving average price of $260.33. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The firm has a market capitalization of $30.67 billion, a P/E ratio of -108.64 and a beta of 0.30. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analysts Set New Price Targets

ALNY has been the subject of a number of research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Redburn Atlantic initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Monday, March 31st. They issued a “buy” rating and a $353.00 target price on the stock. Sanford C. Bernstein reduced their price target on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. StockNews.com lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, March 21st. Finally, William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $316.25.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.